share_log

Pfizer | SC TO-C: Written communication relating to an issuer or third party tender offer

Pfizer | SC TO-C: Written communication relating to an issuer or third party tender offer

辉瑞 | SC TO-C:投标报价书面通信
美股sec公告 ·  07/26 11:18
Moomoo AI 已提取核心信息
Pfizer Inc. has announced modifications to its long-term incentive plans for employees, including executive officers, in response to the impact of the COVID-19 pandemic on its stock price. On July 24, 2024, the Compensation Committee approved changes to the Five-Year Total Shareholder Return Units (TSRUs) and Performance Share Awards (PSAs) granted in 2022 and 2023. These modifications, affecting up to 9,000 active employees, are designed to retain key personnel and align their compensation with the company's long-term performance. The adjustments include the option for eligible participants to extend the terms of their TSRUs by two years, changing the settlement period to 2029 for 2022 grants and to 2030 for 2023 grants. Additionally, the vesting period will be extended to the fifth anniversary of the grant...Show More
Pfizer Inc. has announced modifications to its long-term incentive plans for employees, including executive officers, in response to the impact of the COVID-19 pandemic on its stock price. On July 24, 2024, the Compensation Committee approved changes to the Five-Year Total Shareholder Return Units (TSRUs) and Performance Share Awards (PSAs) granted in 2022 and 2023. These modifications, affecting up to 9,000 active employees, are designed to retain key personnel and align their compensation with the company's long-term performance. The adjustments include the option for eligible participants to extend the terms of their TSRUs by two years, changing the settlement period to 2029 for 2022 grants and to 2030 for 2023 grants. Additionally, the vesting period will be extended to the fifth anniversary of the grant date. The PSAs will also have an extended performance period, with vesting and settlement pushed to 2027 and 2028 for the 2022 and 2023 grants, respectively. The Committee, with advice from an independent compensation consultant, believes these changes will motivate and retain key talent while focusing on stock price recovery. Pfizer plans to initiate a tender offer to allow active employees to accept the modifications, with details to be provided in the Modification Offer documents to be filed with the SEC.
辉瑞公司已针对新冠肺炎疫情对其股价的影响,宣布对其长期激励计划进行调整,包括高管在内的员工。2024年7月24日,薪酬委员会批准了对2022年和2023年授予的五年总股东回报单位(TSRU)和绩效股票奖励(PSA)进行的修改。这些修改适用于多达9,000名在职员工,旨在留住关键人才并让他们的薪酬与公司的长期表现相一致。修改包括让符合条件的参与者选择将其TSRU的期限延长两年,将2022年的股票奖励的结算期改为2029年,将2023年的股票奖励的结算期改为2030年。此外,归属期将延长至股票奖励的授予日期的第五个周年。PSA的绩效期也将延长,将2022年和2023年的股票奖励的归属和结算延迟到2027年和2028年。薪酬委员会在独立的薪酬咨询师建议下,相信这些变更将激励和留住关键人才,并关注股票价格的回升。辉瑞计划发起要约收购,让在职员工接受修改,具体细节将在要约文件中公布并提交给美国证券交易委员会。
辉瑞公司已针对新冠肺炎疫情对其股价的影响,宣布对其长期激励计划进行调整,包括高管在内的员工。2024年7月24日,薪酬委员会批准了对2022年和2023年授予的五年总股东回报单位(TSRU)和绩效股票奖励(PSA)进行的修改。这些修改适用于多达9,000名在职员工,旨在留住关键人才并让他们的薪酬与公司的长期表现相一致。修改包括让符合条件的参与者选择将其TSRU的期限延长两年,将2022年的股票奖励的结算期改为2029年,将2023年的股票奖励的结算期改为2030年。此外,归属期将延长至股票奖励的授予日期的第五个周年。PSA的绩效期也将延长,将2022年和2023年的股票奖励的归属和结算延迟到2027年和2028年。薪酬委员会在独立的薪酬咨询师建议下,相信这些变更将激励和留住关键人才,并关注股票价格的回升。辉瑞计划发起要约收购,让在职员工接受修改,具体细节将在要约文件中公布并提交给美国证券交易委员会。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息